These findings collectively suggest that IS level reduction by AST-120 oral administration in CKD mice or IRF1 gene knockout (KO) in IS-injected mice attenuates DRP1 repression, mitophagic impairment in IECs and intestinal barrier injury. The gene discussed is IRF1; the disease is chronic kidney disease.